Comparative Pharmacology
Head-to-head clinical analysis: BRETHAIRE versus PROVENTIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRETHAIRE versus PROVENTIL.
BRETHAIRE vs PROVENTIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.
Selective beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP
2 inhalations (370 mcg each) by oral inhalation 4 times daily as needed; maximum 12 inhalations per day.
Inhalation: 2 inhalations (90 mcg each) every 4-6 hours as needed; oral: 2-4 mg three to four times daily; extended-release: 4-8 mg every 12 hours.
None Documented
None Documented
3.8 hours (terminal elimination half-life; clinical context: dosing interval typically every 4-6 hours)
Terminal elimination half-life: 3.8–6 hours (inhalation), 3.7–7.1 hours (oral); clinical context: supports dosing every 4–6 hours as needed.
Renal (25% unchanged, 75% as inactive sulfate conjugates), biliary/fecal (minimal)
Renal: ~90% (mostly as sulfate conjugates after oral administration, unchanged drug after inhalation); biliary/fecal: <10%.
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist